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The immunomodulatory potential of cell therapies using adipose-derived stem cells (ASCs)
and bone marrow-derived mesenchymal stem cells (BM-MSCs) has been studied in vas-
cularized composite allotransplantation (VCA). Most cell therapy-based experimental and
clinical protocols integrate some degree of recipient conditioning/induction with antibod-
ies or other immunosuppressive agents. We investigated the susceptibility of ASCs and
BM-MSCs to anti-lymphocyte serum (ALS) and tacrolimus. Rat ASCs and BM-MSCs were
exposed to varying concentrations of tacrolimus and ALS in vitro. Serum from ALS-treated
animals was added to cell cultures. Viability, susceptibility, and cytotoxicity parameters
were evaluated. ALS inhibited ASC and BM-MSC viability and susceptibility in vitro in a
dose-dependent manner. ASCs were more susceptible to both ALS and tacrolimus than
BM-MSCs. Trypsinized and adherent ASCs were significantly smaller than BM-MSCs. This
is the first report on the viability and susceptibility characteristics of BM-MSCs or ASCs
to collateral effects of ALS and tacrolimus. These in vitro insights may impact choice of
cell type as well as concomitant conditioning agents and the logistical coordination of the
timing, dosing, and frequency of drug or cell therapy in solid organ transplantation or VCA
protocols.
Keywords: adipose-derived stem cells, anti-lymphocyte serum, bone marrow-derived stem cells, cell size,
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INTRODUCTION
Vascularized composite allotransplantation (VCA) is an emerging
clinical realm of solid organ transplantation (SOT), that deals with
the restoration of devastating tissue defects secondary to trauma,
congenital malformations, or oncological surgery. VCAs such as
face, limb, or abdominal wall transplants involve multiple tissues
such as skin, fat tissue, muscle, cartilage, tendon, bone, bone mar-
row, lymph nodes, nerve, and vessels among others, which create
a heterogeneous and highly complex immunogenic environment.
In the past 15 years, over 100 upper extremity and 30 face trans-
plantations have been performed under conventional immuno-
suppression protocols similar to SOT with encouraging functional,
immunologic, quality of life and graft survival outcomes (1). One
key barrier for routine clinical feasibility of such life-enhancing
VCA in the need for prolonged immunosuppression with its
coincident adverse effects.
Abbreviations: ALS, anti-lymphocyte serum; ASCs, adipose-derived stem cells;
ATG, anti-thymocyte globulin; BM-MSCs, bone marrow-derived mesenchymal
stem cells; BN rats, Brown Norway rats; CDC, complement-dependent cytotoxicity;
MSCs, mesenchymal stem cells; SOT, solid organ transplantation; VCA, vascularized
composite tissue allotransplantation.
Mesenchymal stem cells (MSCs) represent heterogeneous cell
populations present in multiple tissues (2). Adipose-derived stem
cells (ASCs) and bone marrow-derived mesenchymal stem cells
(BM-MSCs) can differentiate along multiple mesenchymal lin-
eages, such as adipocytes, osteocytes, chondrocytes, myocytes,
and Schwann cells. ASCs and BM-MSCs have been studied
for their tissue repair properties (3, 4). Some soluble fac-
tors are constitutively secreted by MSCs, whereas others are
induced when MSCs are exposed to appropriate inflamma-
tory environments (5). These factors can promote angiogen-
esis, tissue regeneration, extracellular matrix remodeling, cel-
lular recruitment, and immune cell activation or suppres-
sion acting via local or paracrine mechanisms. Multiple pre-
cursor cells, endothelial cells, and pericytes are components
of MSCs (6). These cells respond and home to sites of
injury (7).
Mesenchymal stem cells also possess immunomodulatory and
immunosuppressive properties (5, 8) and experimental studies
have demonstrated that MSCs prolong cardiac and skin graft
survival (9–11). Thus, cell therapies utilizing allogeneic ASCs or
BM-MSCs can expand the scope, relevance, and impact of their
immunomodulatory applications in VCA as well as SOT.
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Bone marrow-derived mesenchymal stem cells have been
widely studied in clinical applications (12–14); however, stud-
ies using ASCs in either VCA or SOT are limited. MSCs have
been evaluated in clinical protocols to support engraftment in
hematological stem cell transplantation, yet some experimental
limitations remain. Paracrine function seems to contribute to
immunomodulation, but the mechanistic basis remains unclear.
MSCs have a propensity for entrapment in the lung capillaries and
liver sinusoids. Various strategies to overcome these limitations,
including repetitive infusion of MSCs (11), preparatory vasodila-
tion, and peripheral arterial administration have been suggested
(15). ASCs seemingly have advantages over BM-MSCs in terms of
clinical translation as cell therapies. One gram of aspirated adipose
tissue yields approximately 3.5× 105–1× 106 ASCs compared to
5× 102− 5× 104 BM-MSCs isolated from 1 g of bone marrow
aspirate (16). Higher cell yields, ease of procurement, expedi-
tious processing, and reportedly superior immunomodulatory
characteristics support use of ASCs in cell therapies (17).
Induction therapy with polyclonal [anti-lymphocyte serum
(ALS) or anti-thymocyte globulin (ATG)] or lytic monoclonal
antibodies alemtuzumab (Campath® 1H) for lymphocyte deple-
tion followed by maintenance treatment with a calcineurin
inhibitor (tacrolimus) has been used in both experimental and
clinical SOT or VCA. Most stem cell-based therapies currently in
Phase I or IIa/b clinical trials in SOT or VCA incorporate recipient
conditioning protocols with antibodies/biologics or calcineurin
inhibitors. There is thus a need to investigate the susceptibility of
stem cells such as ASCs or BM-MSCs to such coincident or simul-
taneous conditioning treatments. The purpose of this study was to
evaluate the collateral effects of ALS or tacrolimus on the viability
and susceptibility characteristics of these cells in vitro.
MATERIALS AND METHODS
ANIMALS
Six- to eight-week-old male Lewis (RT11, recipient, LEW) and
Brown Norway (RT1n, donor, BN) rats weighing 250–300 g
(Harlan, Indianapolis, IN, USA) were maintained in a specific
pathogen-free environment at the University of Pittsburgh. Exper-
iments were performed in accordance with University of Pitts-
burgh Institutional Animal Care and Use Committee (IACUC)
guidelines and approved protocols.
ISOLATION OF RAT ASCs
For stem cell isolation, adipose tissue was collected from bilateral
inguinal fat pads and epididymes of BN rats. On average, 45 g of fat
tissue was harvested from three rats. Enzymatic fat digestion was
performed by collagenase type II (Worthington Biochemical Corp,
Lakewood, NJ, USA) and bovine serum albumin (Millipore, Biller-
ica, MA, USA) in Hanks’ balanced saline solution (Cellgro Medi-
atech Inc., Manassas, VA, USA) for 60 min at 37°C. The digested
tissue was centrifuged at 1,000 rpm for 10 min. The cellular pellet
[stromal vascular fraction (SVF)] was resuspended in erythrocyte
lysis buffer and filtered with sterile gauze. SVF was transferred
to sterile culture flasks with Dulbecco’s modified Eagle’s medium
(DMEM; Cellgro Mediatech, Inc.) plus supplemental Ham’s F-
12 medium (Gibco, Grand Island, NY, USA). After overnight
incubation for cell attachment, non-adherent cells were removed
using a phosphate buffered saline wash. The attached ASCs were
cultured in DMEM/F-12 supplemented with 10% fetal bovine
serum (ATLAS Biologicals, Fort Collins, CO, USA), 0.1µM dex-
amethasone (Sigma-Aldrich, St. Louis, MO, USA), 1% penicillin–
streptomycin (Gibco), and 1.25 mg/L amphotericin B (Gibco).
SVF from 45 g of fat tissue was plated in a T75 flask (BD Falcon).
Approximately, 5× 105 confluent ASCs were obtained (passage 0).
ASCs were expanded in vitro until passage 3.
ISOLATION OF RAT BM-MSCs
Bone marrow-derived mesenchymal stem cells were obtained from
BN rats by flushing their appendicular bones with Roswell Park
Memorial Institute 1640 (RPMI 1640; Lonza, Walkersville, MD,
USA). Three rats were used to isolate BM-MSCs. The cellu-
lar pellet was resuspended in erythrocyte lysis buffer for 3 min.
The reaction was stopped by adding RPMI 1640 supplemented
with 10% fetal bovine serum (ATLAS Biologicals), 2.5µM HEPES
(Sigma-Aldrich), 1% penicillin–streptomycin (Gibco), 1.25 mg/L
amphotericin B (Gibco),1% l-glutamine (Gibco),and 1% Sodium
pyruvate (Gibco), 1% 2-mercaptoethanol (Gibco; basal media for
BM-MSCs), and then centrifuging at 1,750 rpm for 5 min. Cells
were resuspended with the basal media for BM-MSCs and plated
into cell culture flasks. On average, 5× 105cells were obtained once
BM-MSCs were confluent in a T75 flask (passage 0). BM-MSCs
were expanded in vitro until passage 3.
CELL CHARACTERIZATION
Third-passaged BN rat ASCs and BM-MSCs were characterized
using flow cytometry. Aliquots of 5× 105 cells for each cell type
were stained with anti-rat CD29, CD90, CD45 (eBioscience, San
Diego, CA, USA), and CD73 (BD, San Jose, CA, USA) antibodies.
The cells were then analyzed using a BD LSRII flow cytometer
(Becton Dickinson, Franklin Lakes, NJ, USA). Data were analyzed
with FlowJo software (TreeStar Inc., Ashland, OR, USA).
IMAGING AND CELL CHARACTERIZATION WITH IMAGEJ
Plates were imaged and cell phenotype was characterized under a
Nikon Eclipse TS100 (Nikon Instruments Inc., Melville, NY, USA)
at the University of Pittsburgh Center of Biologic Imaging. Cell
sizes were calculated with ImageJ software (National Institute of
Health, Bethesda, MD, USA).
PROLIFERATION AND VIABILITY ASSAYS
Cells were suspended in the basal medium, plated in 96-well
microplates (BD Falcon™) at a density of 1,000 or 5,000 cells/well,
and cultured for 1 and 7 days. MSC and ASC viability was evalu-
ated by MTT assay using a commercially available kit (Millipore,
Billerica, MA, USA). Absorbance was measured at 570–630 nm
with a plate reader (Infinite M200 PRO, Tecan, Morrisville, NC,
USA). The CyQUANT® Cell Proliferation Assay Kit (Invitrogen,
Carlsbad, CA, USA) was used to evaluate cell proliferation, utiliz-
ing green fluorescent dye that binds to cellular nucleic acids. To
assess the influence of ALS and tacrolimus on stem cell viability
and proliferation, rabbit anti-rat lymphocyte serum (25µL; ALS;
CEDARLANE®, Burlington, NC, USA) at different dilutions (0,
2.5, 5, 10, 20, and 40µL/mL) was added to the cells, replacing
the medium. Alternatively, tacrolimus (LC Laboratories, Woburn,
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MA, USA) was added at different concentrations (2, 10, 50, 250,
and 1250 ng/mL). For the agents, in vivo serum concentrations
were calculated as 10–20µL/mL for ALS and 10 ng/mL as trough
levels for tacrolimus. In a different secondary setting, serum from
ALS-pretreated Lewis rats (on injection days −5 and 0) was used
in vitro to evaluate the longer-term depletional effects of ALS.
BN rat ASCs and BM-MSCs were seeded at the density of 5,000
cells per well on day 1. Blood was collected from naïve (n= 3)
and ALS-treated rats (n= 3) on days 0, 1, 3, and 7. The serum of
ALS-treated or naïve rats was added to the cells instead of culture
medium. MTT assay was performed in triplicate using serum from
each animal after 2 h of incubation.
COMPLEMENT-DEPENDENT CYTOTOXICITY ASSAY
Complement-dependent cytotoxicity (CDC) assay was performed
using aCella™-TOX (Cell Technology, Inc., Mountain View, CA,
USA) to simulate transplantation-related complement-associated
cytotoxicity. Briefly, 1 day before the experiment, cells were
seeded at densities of 5,000 and 10,000 cells/25µL/well in a 96-
well microplate. Rabbit anti-rat lymphocyte serum (25µL; ALS;
CEDARLANE®, Burlington, NC, USA) at different dilutions (0,
2.5, 5, 10, 20, and 40µL/mL) was added. There was no anti-
body concentration provided by the manufacturer. The plate was
shaken for 30 s and then placed in a 5% CO2 incubator for 15 min
at 37°C to allow the cells to opsonize. Rat complement serum
(25µL; Fitzgerald Industries International, Acton, MA, USA) was
added to the appropriate wells to start the reaction. Upon shak-
ing for 30 s, the plate was incubated at 37°C in the CO2 incubator
for 30 min. The plate was then removed from the incubator and
allowed to cool down to room temperature (RT) for 15 min. The
target cells in the maximum lysis control wells were then lysed
by adding 10µL of the lysis buffer, and the plate was incubated
on the bench top for an additional 5 min at RT. One-hundred
twenty five microliters of basal medium was added to each well
to reach a total volume of 200µL. The plates were centrifuged for
1 min at 750 rpm. Fifty microliters of the enzyme assay diluent
was transferred to the appropriate wells of an opaque white lumi-
nescence plate. Fifty microliters of each reaction supernatant was
transferred to wells containing the assay diluent. One-hundred
microliters of 2× enzyme assay reagent (containing G3P), fol-
lowed by 50µL of 1× detection reagent was added to each diluted
supernatant. The plates were again shaken for 30 s and immedi-
ately read in luminescence mode using the plate reader at 5 min
intervals.
STATISTICAL ANALYSIS
InStat (Version 3.0, GraphPad, San Francisco, CA, USA) was
used for statistical analysis. Data are presented as means± SD.
Differences between the groups or sites of measurements were
assessed by unpaired analysis of variance. A P value of <0.05 was
considered statistically significant.
RESULTS
CELL CHARACTERIZATION, MORPHOLOGY, AND SIZE
Random sampling and flow cytometry analysis confirmed the
CD45−CD29+CD90+CD73+ phenotype in morphologically uni-
form cultures of BN rat ASCs and BM-MSCs (Figure 1). Both
third-passaged adherent ASCs and BM-MSCs were spindle-shaped
and morphologically similar (Figures 2A,C). However, the sizes
of attached ASCs and BM-MSCs varied between 100.81± 25.14
and 258.06± 49.46µm, respectively (P < 0.01). The diameter of
trypsinized cells was significantly smaller and differed between
16.6± 3.1µm (ASCs) and 45.5± 5.6µm (BM-MSCs), respec-
tively (P < 0.01; Figures 2B,D,E).
VIABILITY ASSAY
Figure 3 shows cell viability with the MTT assay on day 1
(Figures 3A,C) and day 7 (Figures 3B,D) when cells were exposed
to increasing concentrations of ALS. Measurements were taken
in triplicates, showing a dose-dependent decrease of cell viabil-
ity on days 1 and 7 in the presence of ALS. All the values were
subtracted from those of the media only group (no cell group).
ASCs seemed to be slightly more susceptible to these ALS-related
effects compared to BM-MSCs on day 7. Compared to BM-MSCs,
ASC viability decreased to 53.92± 8.33% and 78.12± 4.79% at a
concentration of 5µL/mL at days 1 and 7. The acute effects of
tacrolimus on cell viability were not significant in the first 24 h for
ASCs and BM-MSCs. However, after incubation with tacrolimus
for 7 days, both cell types revealed a dose-dependent sensitiv-
ity to the drug. ASCs were comparably more susceptible, with
viability decreasing to 88.6± 22.91% at 2 ng/mL tacrolimus and
77.26± 6.13% at 1250 ng/mL. BM-MSCs reacted to tacrolimus
concentrations of 250 and 1,250 ng/mL, (with decreases in cell
counts to 97.63± 2.08 and 97.20± 6.77%), respectively, but not
at lower concentrations (Figures 3C,D).
PROLIFERATION ASSAY
The CyQUANT assay for cell proliferation showed clear dose-
dependent effects for ASCs under the influence of ALS (Figure 4).
Cells were exposed to ALS over 24 h (Figure 4A) and 7 days
(Figure 4B). All the values were subtracted from those of the
media only group (no cell group). At 5µL/mL ALS, the pro-
liferation of ASCs was markedly reduced at both time points
compared to the vehicle group. Increased concentrations of ALS
led to an arrest of proliferation. For BM-MSCs, the effect was
observed only at concentrations above 10µL/mL. After the addi-
tion of tacrolimus, no marked reaction was detectable within 24 h.
After 7 days, ASCs showed a dose-dependent reduction of pro-
liferation rates at very high concentrations, similar to the effect
observed for BM-MSCs (Figures 4C,D). The maximal decrease of
proliferation was 52.9± 3.35% for ASCs and 81.24± 4.40% for
BM-MSCs, respectively, at 1250 ng/mL. ASCs had higher levels
of proliferation on day 1 with gradual reduction in prolifer-
ation toward day 7 (Figure 4C), while BM-MSC proliferation
improved with tacrolimus incubation reaching higher levels at day
7 (Figure 4D).
SERUM EFFECTS ON CELL VIABILITY
Replacing the culture medium of stem cells in vitro with serum
from ALS-treated rats reduced the viability of ASCs significantly
(Figure 5A). On day 1, viability decreased to 71.53± 21.27%,
which was significant compared to day 2. Tests performed at later
time points did not reveal this early detrimental effect. BM-MSCs,
however, showed a similar but delayed decrease of viability with
significant differences after day 2 (Figure 5B).
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FIGURE 2 | Cell morphology and size. Morphology of cultured adherent
and trypsinized BN rat ASCs (A,B) and BM-MSCs (C,D). Scale
bar=100µm. (E) ASC and BM-MSC cell size. Sizes of adherent and
trypsinized ASCs (blue bars) and BM-MSCs (red bars). **P <0.01 vs. ASCs.
COMPLEMENT-DEPENDENT CYTOTOXICITY ASSAY
The CDC assay was utilized to detect cell lysis based
on glyceraldehyde-3-phosphate dehydrogenase (GAPDH)-release
using rat complement as a probe in the presence of ALS. Whereas
the negative control (cells and 40µL/mL of ALS) did not show
a strong response (Figure 6), low concentrations of ALS revealed
a CDC with a strong dose-dependency. ASCs did not succumb
to these complement-mediated effects to the same extent as BM-
MSCs and showed lower levels of luminescence compared to that
with BM-MSCs (Figure 6A vs. Figure 6B). Maximal lysis con-
trol was obtained by the combination of cells, complement, ALS
(40µL/mL), and lysis buffer.
DISCUSSION
The success of cell-based immunomodulation depends on facil-
itating graft acceptance, or ideally tolerance, in the absence of
graft-versus-host disease in the field of transplantation. Various
drugs and antibodies have been introduced for induction ther-
apy and maintenance-immunosuppression in clinical SOT and
have been widely used in clinical VCA protocols (18). All these
agents have proven immunosuppressive efficacy, but their collat-
eral bystander effects on specific cell types in the recipient as well
on BM-MSCs or ASCs have thus far been less well investigated.
Clinical protocols utilize tolerance induction with lympho-
depleting antibodies like ATG or alemtuzumab to suppress the
recipient alloresponses. ALS is analogous to ATG and has been
evaluated in experimental models of SOT as well as VCA (19).
However, the potential detrimental effects of the depletion regi-
men on MSC viability, proliferation, differentiation, recruitment,
and function, as well as on their immunomodulatory potential
remain undetermined. Several SOT clinical trials have evaluated
BM-MSCs or ASCs as cell therapy strategies in combination
with conventional induction/maintenance-immunosuppression
and documented the utility and efficacy of such therapies in facil-
itating reduction of dosing/intensity, frequency, or duration of
immunosuppression (20, 21). Perico et al. first demonstrated the
effect of ATG on BM-MSCs in vitro (20). They exposed BM-
MSCs to serum from ATG-treated kidney transplant patients taken
postoperatively on days 7 and 14, and found a very low percent-
age of ATG bound to BM-MSCs compared with ATG bound to
peripheral blood mononuclear cells. Franquesa et al. conducted
the experiment to test the effect of ATG on ASCs. They tested
0.5–100 ng/mL of ATG, and found that ATG reduced the viabil-
ity and antiproliferative capacity of ASCs in a dose-dependent
manner and converted them into targets for CD8+ T cells and
natural killer T-cell lysis (22). Polyclonal antibodies such as ATG
or ALS are well known induction agents which seemingly are
deleterious to stem cell therapies injected concurrently with anti-
body treatment. The fraction of ASCs or BM-MSCs that remain
viable after ALS treatment could proliferate as shown by our
results.
Adipose-derived stem cells and BM-MSCs are quite similar
in cell surface markers; they are positive for CD29, 73, and 90
and negative for CD45 (Figure 1). Also, they are similar in their
proliferative capacity. Studies have shown that primary cultures
reach 70–80% confluence in approximately 7–9 days for BM-
MSCs and 5–6 days for ASCs (23). In our experiment, both ASCs
and BM-MSCs became 80% confluent within 7 days, and were
passaged every 7 days. Our results exhibit functional differences
for ASCs and BM-MSCs in terms of susceptibility to ALS as well
as tacrolimus. The most important finding in our study was that
ASCs are more susceptible to the toxicity of ALS and tacrolimus
than BM-MSCs (Figures 3B,D and Figures 4B,D). The ALS doses
used in vitro were calculated to ensure comparability with ALS
dosing used in conventional clinical induction protocols. Further,
ASCs and BM-MSCs differ in their sensitivity to ALS in peak
loss of viability by the timing of exposure to ALS (Figure 5).
The influence of tacrolimus on ASC and BM-MSC viability and
susceptibility was more pronounced after 7 days of incubation
than the immediate effect after 1 day in our study. BM-MSCs
demonstrated slightly higher susceptibility to tacrolimus at higher
dosages than ASCs. Some of these findings were confirmed in
earlier studies with human muscle derived-MSCs (MD-MSCs)
exposed to select antibodies or drugs used in SOT. Hoogduijin
et al. reported that high systemic tacrolimus levels concentra-
tion (100 ng/mL) were detrimental to MD-MSC survival after
incubation over one week (24). Pre-incubation of MD-MSCs
with tacrolimus, however, augmented their immunosuppressive
effect. Interestingly, MD-MSCs inhibited tacrolimus-induced sup-
pression of alloactivated mononuclear cells. Other studies with
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FIGURE 3 | Cell viability under drug exposure. MTT assay showing cell
viability on day 1 (A,C) and day 7 (B,D) after adding various concentrations of
ALS or tacrolimus. ALS had a suppressive effect on both ASCs and BM-MSCs
at higher concentrations from day 1 through day 7 (A,B). Tacrolimus had a
suppressive effect on ASCs on day 7 (C,D). *P <0.05 vs. vehicle group at
each time point.
FIGURE 4 | Cell proliferation under drug exposure. CyQUANT assay
results with a clear dose-dependent effect for ASCs and BM-MSCs under
ALS-influence on days 1 (A) and 7 (B). CyQUANT assay results after
adding tacrolimus on day 1 (C) and day 7 (D). CyQUANT assay results are
consistent with the MTT assay results. *P <0.05 vs. vehicle group at each
time point.
BM-MSCs demonstrated disparate positive or negative effects
of immunosuppressive agents such as tacrolimus, rapamycin, or
mycophenolic acid mofetil on human BM-MSCs (25, 26).
In addition, we were able to obtain data on the morpho-
logical differences between ASCs and BM-MSCs, especially for
trypsinized cells, which are relevant to route of application.
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FIGURE 5 | ASC and BM-MSC susceptibility to ALS. ASC [blue bars, (A)]
and BM-MSC [red bars, (B)] were incubated for 2 h in 100% serum from
ALS-treated or untreated naïve rats. An MTT assay was performed on days
1, 2, 4, and 8. The direct absorbance ratio of cells exposed to serum (as
conditioned medium) from ALS-treated and naïve rats is presented. Data
are expressed as mean±SD. **P <0.01 vs. other days.
In the morphological study, we demonstrated that BM-MSCs
(Figures 2B,D,E) were significantly larger in size as compared
to ASCs (Figures 2A,C,E). Larger size could make the cells more
prone to lung entrapment with reduction of their peripheral hom-
ing capacity. This theory is reinforced by recent reports of entrap-
ment of MSCs in the lung capillaries following systemic delivery
(27, 28) and may indeed limit clinical impact of BM-MSCs. Var-
ious strategies, including peripheral arterial administration (15)
or repetitive application to increase the lung bypass have been
suggested (27). To our knowledge, this is the first direct morpho-
logical comparison of these two MSC types in regards to cell size.
Our results show that trypsinized ASCs are only 30% in diameter
compared to trypsinized BM-MSCs. In this regard, we speculate
that ASCs can more effectively pass the pulmonary capillary bed
with less entrapment. Fischer et al. (27) demonstrated that repet-
itive cell administration would prevent stromal cell loss from the
circulation. Repetitive application of ASCs and BM-MSCs has also
been reported as a successful strategy for immunomodulation in
rat and pig hind-limb transplantation (29, 30).
Our in vitro outcomes of the CDC assay advocate for the use
of ASCs rather than BM-MSCs in a transplant setting. ASCs seem
to be more resistant to the cytotoxic effects mediated through the
complement system as tested under the influence of ALS in our
FIGURE 6 | Complement-dependent cytotoxicity (CDC) under drug
exposure. CDC assay results for ASCs (A) and BM-MSCs (B). Higher
concentrations of ALS showed cytotoxic effects on BM-MSCs but not
ASCs. *P <0.05 vs. maximal lysis group (cells+ALS40+ complement+
lysis buffer).
study. This may impact stem cell viability or functional efficacy
in the early post-transplant phase. To our knowledge, the suscep-
tibility of MSCs has not been tested earlier with regards to the
complement system and transplantation.
Our study is the first to characterize the specific effects of two
of the most widely used induction and maintenance immuno-
suppressive agents in SOT (ALS and tacrolimus). Our data offers
critical early insights into comparative susceptibility or relative
resistance of viability or proliferative capacity of BM-MSCs or
ASCs to collateral effects of these agents. These in vitro data sup-
port the hypothesis that phenotypic, viability, and proliferative
characteristics of ASCs or BM-MSCs may positively or negatively
impact their homing, survival, and key functional efficacy in vivo
especially when cell therapy protocols logistically overlap with
depletional induction/maintenance regimens. These variables are
important to consider in the determination of appropriate timing,
dosing, frequency, and cell-type choice in cell therapy protocols
used adjunctively with conventional immunosuppressive induc-
tion or maintenance regimens. We are currently exploring in vivo
translation of these findings in experimental limb VCA models.
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